Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

prasco laboratories - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone 10 mg - prednisolone sodium phosphate orally disintegrating tablets are indicated in the treatment of the following diseases or conditions: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: - atopic dermatitis - drug hypersensitivity reactions - seasonal or perennial allergic rhinitis - serum sickness - bullous dermatitis herpetiformis - contact dermatitis - exfoliative erythroderma - mycosis fungoides - pemphigus - severe erythema multiforme (stevens-johnson syndrome) - congenital adrenal hyperplasia - hypercalcemia of malignancy - nonsuppurative thyroiditis - primary or secondary adrenocortical insufficiency: hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable. during acute episodes in: - crohn's disease - ulcerative colitis - acquired (autoimmune) hemolytic anemia - diamond-blackfan anemia - idiopathic thrombocytopenic purpura in

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

mission pharmacal company - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone 25 mg in 5 ml - prednisolone sodium phosphate oral solution (25 mg prednisolone per 5 ml) is indicated in the following conditions: 1. allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. dermatologic diseases pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (stevens-johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. edematous states to induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephritic syndrome, without uremia. 4. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; i

Kenija - anglų - Pharmacy and Poisons Board

betamethasone sodium phosphate - eye drops - each ml contains: betamethasone sodium phosphate… - betamethasone and antiinfectives

Izraelis - anglų - Ministry of Health

organon pharma israel ltd., israel - betamethasone as dipropionate; betamethasone sodium phosphate - suspension for injection - betamethasone sodium phosphate 2 mg/ml; betamethasone as dipropionate 5 mg/ml - betamethasone - betamethasone - produces anti-inflammatory, anti rheumatic and anti-allergic action and is indicated for systemic and local therapy of acute and chronic corticosteroid-responsive disorders.

Airija - anglų - HPRA (Health Products Regulatory Authority)

rph pharmaceuticals ab - betamethasone sodium phosphate - ear/eye/nasal drops, solution - 0.1 percent weight/volume - corticosteroids; betamethasone

Malaizija - anglų - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

y.s.p. industries (m) sdn bhd - betamethasone dipropionate; betamethasone sodium phosphate -

Kenija - anglų - Pharmacy and Poisons Board

laboratory & allied ltd p.o box 42875 gpo 00100 nairobi, kenya - betamethasone sodium phosphate neomycin sulphate… - ear/eye drops, solution - betamethasone sodium phosphate bp 0.1 % w/v … - otological anti-infectives

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

physicians total care, inc. - betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone valerate - unii:9ifa5xm7r2) - betamethasone valerate 1 mg in 1 g - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of cortico-steroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Japonija - anglų - すりの適正使用協議会 RAD-AR Council, Japan

shionogi & co., ltd. - betamethasone acetate; betamethasone sodium phosphate - injection

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - betamethasone valerate 1.2 mg in 1 g - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.